Patients in East Central Indiana facing complex medical conditions like Alzheimer’s, Crohn’s disease, and multiple sclerosis no longer have to travel long distances for specialized care.

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus, and other devastating autoimmune diseases – by reprogramming patients’ out-of-whack immune ...

He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...

Patients in East Central Indiana facing complex medical conditions like Alzheimer’s, Crohn’s disease, and multiple sclerosis no longer have to travel long distances for specialized care. Hancock ...

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

The device is covered by Medicare but not by all commercial insurance, particularly Blue Cross Blue Shield.

This newly FDA-approved system offers a groundbreaking device for adults with RA. VENTURA, Calif., March 11, 2026 /PRNewswire/ -- With nearly 1.5 million Americans suffering from rheumatoid arthritis ...

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes ...